Ovagen Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Ovagen dosing — protocols, safety, and where to buy.
Dose Range
10 mg oral capsule, 1-2 daily for 10-30 days
Dosage Calculator
Calculate exact dosing for Ovagen.
Dosing Protocols
Beginner Ovagen Protocol (first reproductive-focused cycle)
- Product form: 20 mg oral capsule from vendor with third-party HPLC and certificate of analysis.
- Dose: 1 capsule (20 mg) once daily, sublingual or oral on empty stomach 30–45 min before breakfast.
- Duration: 10 consecutive days.
- Washout: 60 days before repeat cycle.
- Monitoring: Baseline cycle diary (menses dates, symptoms, hot flushes VAS, sleep quality). Endocrine labs (FSH, estradiol, AMH, TSH) if not done in past 6 months. Continue through cycle and for 2-3 subsequent menstrual cycles.
- Continue existing reproductive medicine care. Do not stop HRT, contraception, or fertility treatment to test Ovagen alone.
- Stop criteria: Abnormal bleeding (not consistent with typical cycle), severe menstrual changes, new pelvic pain, rash, severe headache, new neurological symptoms.
- Setting expectations: Most users report mild subjective effects — slightly improved energy, modest reduction in perimenopausal symptoms if applicable. Do not expect restoration of fertility or reversal of menopause. A 10-day bioregulator cycle does not regrow oocytes.
- Avoid during pregnancy or active conception attempts. Use during ovulation-tracking conception windows requires discussion with reproductive clinician.
Intermediate Ovagen Protocol (experienced bioregulator user)
- Product form: 20 mg oral capsule or lyophilised synthetic KEDG peptide (requires reconstitution).
- Dose: 20 mg oral daily OR 2–5 mg SC daily.
- Duration: 10 consecutive days per cycle.
- Cycling: Twice yearly typical.
- Rotation: With Epitalon, Pinealon, Thymogen. Can pair with Testagen for couples considering both female and male reproductive support — use different cycles for each partner.
- Monitoring: Annual reproductive endocrine panel (FSH, LH, estradiol, AMH, TSH, prolactin), cycle tracking, symptom VAS.
- Stack integration: Continue evidence-graded reproductive care. Bioregulator is experimental layer.
- Documentation: Cycle log.
- Expectations: Subjective effects remain modest. Biomarker changes are usually within normal age-related trends.
- Cost: Annual Ovagen cycling 150–300 USD. Reproductive endocrinology consultation or comprehensive endocrine workup delivers more actionable reproductive information.
Advanced Ovagen Protocol (Khavinson reproductive rotation)
For experienced Khavinson users with stable reproductive-hormone baseline.
- Annual rotation:
- Month 1, Days 1–10: Ovagen 20 mg oral/sublingual daily OR 5 mg SC daily.
- Months 2–3: Washout.
- Month 4, Days 1–10: Epitalon 5–10 mg SC daily.
- Months 5–6: Washout.
- Month 7, Days 1–10: Pinealon 10 mg oral daily (HPG axis support).
- Months 8–9: Washout.
- Month 10, Days 1–10: Ovagen repeat.
- Months 11–12: Washout.
- Monitoring: Baseline and annual reproductive endocrine panel, pelvic ultrasound if indicated, cycle and symptom tracking.
- Stack on evidence-graded base: Hormone therapy if indicated and not contraindicated, myo-inositol 2–4 g BID if applicable, vitamin D, omega-3, CoQ10. The bioregulator is experimental add-on.
- Reproductive endocrinologist coordination.
- Stop and reassess: Any abnormal bleeding, pelvic pain, new masses, or unexpected symptoms warrants evaluation.
- Do not run during active IVF or fertility treatment without explicit reproductive endocrinologist approval.
- Realistic expectation: Advanced protocol is a ritual on top of evidence-graded care. Will not reverse established menopause, restore fertility in primary ovarian insufficiency, or substitute for specific reproductive medicine interventions.
Commonly Stacked With
Stacking Notes
Khavinson rotation
Ovagen cycles alongside Testagen (complementary male/female reproductive pair), Epitalon, Pinealon, Thymogen, Vilon, Livagen, Bronchogen, Cardiogen, Cartalax, and Chonluten.
A female reproductive-focused rotation:
- Days 1–10: Ovagen 20 mg oral/sublingual daily
- Days 11–70: Washout
- Days 71–80: Epitalon 5–10 mg SC daily (general anti-aging, pineal modulation)
- Days 81–140: Washout
- Days 141–150: Pinealon 10 mg oral daily (hypothalamic-pituitary support)
- Days 151–210: Washout
- Days 211–220: Ovagen repeat cycle
Evidence-graded reproductive stack (preferred)
- Comprehensive endocrine assessment — first step, always.
- Lifestyle optimisation — weight, smoking, stress, sleep, exercise.
- Reproductive endocrinologist consultation if fertility concerns or severe perimenopausal symptoms.
- Hormone therapy (estradiol + progestogen) for perimenopausal symptoms when indicated and not contraindicated.
- Ovulation induction (clomiphene, letrozole) or IVF for fertility treatment as indicated.
- CoQ10 200–600 mg daily — modest mitochondrial support evidence.
- Myo-inositol 2–4 g BID — RCT evidence in PCOS.
- Vitamin D 1000–4000 IU daily.
- Omega-3 EPA/DHA 2–4 g daily.
- DHEA 25–50 mg daily in select reproductive-medicine protocols.
- Experimental bioregulators (Ovagen, Testagen, Epitalon) as tier-11 add-ons.
Stacking with hormone therapy
No documented interactions. Theoretically, Ovagen layered on top of HRT does not obviously conflict, but the combination has not been formally studied. If on HRT, continue it and add Ovagen as an experimental adjunct.
Stacking with fertility treatment
Do not run Ovagen during active IVF cycles without reproductive endocrinologist knowledge. The unvalidated mechanism could theoretically affect ovarian response, and no data exist on safety during controlled ovarian hyperstimulation.
Stacking with hormonal contraception
Continue combined hormonal contraception if prescribed for contraception. Ovagen does not affect contraceptive efficacy through any known mechanism but also has not been formally studied. Do not use Ovagen for contraception.
Stacking with supplements
Epitalon + Ovagen is the most common community pair for women focused on reproductive aging and general longevity. Safe combination from an interaction standpoint. CoQ10, myo-inositol, vitamin D, and omega-3 all layer safely with Ovagen cycles.
Stacking with DHEA
DHEA is sometimes used in reproductive medicine for diminished ovarian reserve (controversial but some evidence). Combining DHEA with Ovagen is not documented but is theoretically compatible. Do not initiate DHEA without reproductive endocrinologist involvement.
Contraindicated combinations
Do not substitute for evidence-based reproductive medicine. Do not delay fertility treatment to test Ovagen alone. Do not use in hormone-sensitive cancer without oncology approval (and in most cases, avoid entirely).
Side Effects & Safety
Contraindications
## Contraindications ### Absolute contraindications - **Pregnancy** - **Breastfeeding** - **Active conception attempts** — avoid pending more safety data - **Paediatric and adolescent use** - **Hormone-sensitive cancer** (breast, endometrial, ovarian, cervical — active or recent history) - **Unexplained abnormal uterine bleeding** — requires evaluation before any hormonal-framework intervention - **Active pelvic mass or gynaecological pathology** under investigation - **Known hypersensitivity** to Ovagen or any Khavinson bioregulator ### Relative contraindications (supervised use only) - **Active IVF or fertility treatment** — reproductive endocrinologist approval required - **Recent pelvic surgery** — coordinate with surgeon - **History of VTE or thrombophilia** — unquantified thrombotic risk - **History of hormone-sensitive benign conditions** (large fibroids, endometriosis, atypical endometrial hyperplasia) — gynaecology coordination - **Severe liver disease** - **Severe renal impairment (eGFR <30)** ### Use with caution - **Current HRT or hormonal contraception** — no interaction data but compatibility appears acceptable - **PCOS management** — do not substitute for evidence-based PCOS treatment - **Thyroid disease** — treat thyroid, do not substitute Ovagen for thyroid therapy ### Quality-of-supply contraindication Do not use from vendors without third-party HPLC peptide content confirmation and endotoxin testing. ### Symptoms requiring evaluation, not bioregulators Abnormal uterine bleeding, new pelvic pain, new pelvic mass, unexplained weight loss, severe menopausal symptoms not responsive to standard care — require gynaecological/reproductive endocrinology evaluation, not Ovagen self-treatment.
Additional Notes
Dosage Notes
Oral/sublingual dosing
- 1 capsule (20 mg nominal) once daily
- Sublingual preferred ~60 seconds
- Empty stomach 30–45 min before first meal
- Duration 10 days per cycle
- Washout 60–90 days
20 mg capsule = undisclosed actual KEDG content (historically 2–4 mg).
Subcutaneous dosing
- 2–5 mg SC once daily (synthetic peptide)
- 10 consecutive days per cycle
- 60-day washout
Intravaginal or topical dosing
Not a Khavinson convention. Some community experimenters explore topical/intravaginal application, but no published protocol and no sterility/concentration guidance exists. Do not attempt without medical supervision.
Cycling relative to menstrual cycle
No specific cycle-phase timing is recommended in Khavinson literature. Most users run the 10-day cycle without reference to menstrual phase. Some users anecdotally prefer starting cycles in the follicular phase (days 1–14 from menses onset).
Maximum dose
Do not exceed 20 mg oral or 5 mg SC daily.
Continuous dosing
Do not run continuous cycles. Safety of continuous exposure unstudied.
Age considerations
Russian studies enrol perimenopausal and older women. Premenopausal women with normal cycles have less theoretical benefit (or theoretical risk of cycle disruption). No paediatric or adolescent use.
Pregnancy, breastfeeding, active conception
Avoid during pregnancy, breastfeeding, and active conception attempts until safety data exist. The theoretical ovarian-transcription-modulating mechanism creates concern in early pregnancy.
Renal and hepatic impairment
No formal dose adjustment. Avoid in eGFR <30 and decompensated hepatic disease.
Frequently Asked Questions
What is the recommended Ovagen dosage?
The typical dose range for Ovagen is 10 mg oral capsule, 1-2 daily for 10-30 days. Always start with the lowest effective dose.
How often should I take Ovagen?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Ovagen need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Ovagen side effects?
## Side Effects and Safety Ovagen short-term safety signal from Russian literature is mild. Long-term pharmacovigilance is effectively absent. ### Reported short-term adverse effects - **Gastrointestinal:** mild nausea, dyspepsia. Usually self-limited. - **Headache:** occasional mild headache. - **Menstrual changes:** occasional transient cycle variation (early or delayed menses, light spotting). Generally self-limited. - **Mood and sleep:** variable. - **Rare allergic reactions:** occasional mild rash. - **No reports of serious reproductive adverse events** attributable to Ovagen at convention dosing. ### Theoretical concerns - **Hormone-sensitive tumour risk.** Breast cancer, endometrial cancer, and ovarian cancer are hormone-sensitive malignancies. If Ovagen modulates ovarian or reproductive transcription programmes (as claimed), off-target effects on proliferative pathways could theoretically exist. Literature has not been designed to detect this. Patients with history of or current hormone-sensitive cancer should not use Ovagen. - **Endometrial hyperplasia.** Unopposed estrogenic effects (if any) theoretically raise endometrial hyperplasia risk. No data characterise endometrial effects of Ovagen. - **Thrombosis risk.** Hormone therapy carries VTE risk. Whether Ovagen has any prothrombotic effect is unknown. - **Drug interactions.** No formal studies. Theoretical interactions with hormonal contraceptives, HRT, ovulation induction agents, or hormone-sensitive cancer therapies are not characterised. ### Pregnancy and breastfeeding No reproductive toxicology data. Do not use during pregnancy or when actively trying to conceive until more data exist — the theoretical mechanism of ovarian transcription modulation creates concern in early pregnancy. Avoid in breastfeeding. ### Paediatric use Do not use in children or adolescents. Reproductive-system development is particularly sensitive to transcriptional modulators. ### Hormone-sensitive cancer Do not use in active or recent history of: - Breast cancer - Endometrial cancer - Ovarian cancer - Cervical cancer (though less clearly hormone-sensitive) ### Active reproductive disease Unexplained abnormal uterine bleeding, persistent pelvic pain, new pelvic mass, or any abnormal gynaecological finding should be evaluated by a clinician before considering experimental bioregulator use. ### Perimenopause and menopause Patients with severe perimenopausal symptoms should have access to evidence-graded hormone therapy discussion before experimenting with Ovagen. HRT with individualised risk-benefit is a proven therapy with decades of data; Ovagen is a speculative alternative. Do not substitute Ovagen for discussed-and-declined HRT without understanding the evidence difference. ### Polycystic ovarian syndrome (PCOS) PCOS has well-established management (lifestyle, metformin, inositol, combined hormonal contraceptives, ovulation induction when conception desired). Ovagen is not a substitute for PCOS management. ### Endometriosis Evidence-graded endometriosis management (hormonal suppression, surgical excision) should not be delayed to test Ovagen. ### Supply quality Require third-party HPLC and endotoxin testing. Unverified product is not appropriate for reproductive-system applications. ### Overall assessment Short-term signal mild. Long-term characterisation effectively absent. Particularly concerning in hormone-sensitive cancer context, pregnancy, and during active fertility treatment. Treat as experimental with reproductive-specific contraindications strictly enforced.
Where can I buy Ovagen?
Visit our vendor directory to find trusted sources for Ovagen.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.